Myriad Genetics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Mark Steven Davis, a Director of Myriad Genetics Inc, sold 6,100 shares of common stock on November 18, 2026 for $5.62 per share.
NASDAQ
Raj Jampa, Chief Technology Officer of Myriad Genetics Inc, received 58,560 shares of common stock on November 6, 2026.
NASDAQ
Vishal Sikri, EVP, Commercial of Myriad Genetics Inc, received 53,236 shares of common stock on November 6, 2026.
NASDAQ
Shereen Solaiman, Chief People Officer of Myriad Genetics Inc, received 83,049 shares of common stock on November 6, 2026.
NASDAQ
Jennifer Lynne Fox, Chief Legal & Corp Strategy of Myriad Genetics Inc, received 139,267 shares of common stock on November 6, 2026.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc, received 92,632 shares of common stock on November 6, 2026.
NASDAQ
Mark Verratti, Chief Operating Officer of Myriad Genetics Inc, received 146,933 shares of common stock on November 6, 2026.
NASDAQ
Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc, received 121,379 shares of common stock on November 6, 2026.
NASDAQ
Jennifer Lynne Fox, Chief Legal & Corp Strategy of Myriad Genetics Inc, received 39,370 shares of common stock on November 1, 2026.
NASDAQ
Brian J Donnelly, Chief Commercial Officer of Myriad Genetics Inc, reported multiple transactions in common stock on September 16, 2026.
NASDAQ
Vishal Sikri, EVP, Commercial of Myriad Genetics Inc, received 257,731 shares of common stock on September 16, 2026.
NASDAQ
Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics Inc, reported a transaction in 4,398 shares of common stock on September 3, 2026.
NASDAQ
Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc, reported a transaction in 8,761 shares of common stock on August 16, 2026.
NASDAQ
Myriad Genetics President and CEO Samraat S. Raha acquired 3,542 shares of common stock through the company's employee stock purchase plan.
NASDAQ
Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of Myriad Genetics common stock via the employee stock purchase plan.
NASDAQ
Myriad Genetics Director Rashmi Kumar reported a sale of 15,000 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Director Daniel Skovronsky was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the company's 2026 equity incentive plan.
NASDAQ
Director Lee Nisley Newcomer was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Director Mark Steven Davis was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Director S. Louise Phanstiel was granted 59,701 restricted stock units in Myriad Genetics, Inc.
NASDAQ
Director Heinrich Dreismann acquired 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Director Colleen F. Reitan was granted 59,701 restricted stock units by Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Director Paul Bisaro was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Director Rashmi Kumar was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.
NASDAQ
Myriad Genetics Chief Technology Officer, Jampa Raj, received a grant of 251,889 restricted stock units.
NASDAQ
Director Paul Bisaro purchased 7,500 shares of Myriad Genetics common stock at an average price of $3.685 per share.
NASDAQ
Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics Inc., reported a transaction involving the withholding of common stock to cover tax obligations.
NASDAQ
Myriad Genetics Chief Operating Officer Mark Verratti had 1,069 shares withheld to satisfy tax obligations upon the vesting of restricted stock units.
NASDAQ
Chief Scientific Officer Dale Muzzey disposed of 946 shares of Myriad Genetics common stock to satisfy tax obligations.
NASDAQ
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, disposed of 2,019 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.